Possible paths and potential barriers to successfully modeling drug resistance.

about

Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues Forward: combating resistance: infectious diseases.

P2860

Q36562337-D0BC35F9-AE3A-46B6-83A5-F1957E4C764B Q51394206-2100B10A-26B0-411A-97CE-DACDCF56239C

P2860

Possible paths and potential barriers to successfully modeling drug resistance.

Item

http://www.wikidata.org/entity/Q43833882

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Possible paths and potential barriers to successfully modeling drug resistance.

@en

Possible paths and potential barriers to successfully modeling drug resistance.

@nl

type

Item

label

Possible paths and potential barriers to successfully modeling drug resistance.

@en

Possible paths and potential barriers to successfully modeling drug resistance.

@nl

prefLabel

Possible paths and potential barriers to successfully modeling drug resistance.

@en

Possible paths and potential barriers to successfully modeling drug resistance.

@nl

P1476

Possible paths and potential barriers to successfully modeling drug resistance.

@en

P2093

Amy C Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

Predicting resistance mutations using protein design algorithms

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

Development of an in silico model for predicting efflux substrates in Caco-2 cells.

Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ

Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

P304

1181-1183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4155/FMC.13.78

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23859198

http://www.w3.org/2001/XMLSchema#string

Possible paths and potential barriers to successfully modeling drug resistance.

about

P2860

P2860

Possible paths and potential barriers to successfully modeling drug resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698